A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

Trial Profile

A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2014

At a glance

  • Drugs AIM 102 (Primary)
  • Indications Allergic asthma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors AIM Therapeutics
  • Most Recent Events

    • 13 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 22 Oct 2012 Status changed from recruiting to active, no longer recruiting, as reported in an AIM Therapeutics media release.
    • 22 Oct 2012 AIM Therapeutics anticipates that trial results will be available by the end of the first quarter, 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top